Plus Therapeutics (NASDAQ:PSTV) Receives Buy Rating from D. Boral Capital

Plus Therapeutics (NASDAQ:PSTV)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a research note issued on Thursday,Benzinga reports. They presently have a $5.00 target price on the stock.

PSTV has been the topic of several other reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Plus Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, August 16th. Ascendiant Capital Markets reduced their price objective on shares of Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating on the stock in a research note on Friday, November 21st. Zacks Research lowered Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 11th. Finally, Maxim Group reduced their price target on Plus Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research report on Monday, August 18th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.25.

Plus Therapeutics Stock Up 6.5%

Shares of PSTV stock traded up $0.04 on Thursday, reaching $0.72. The company had a trading volume of 5,001,047 shares, compared to its average volume of 18,478,025. The business’s 50-day moving average is $0.61 and its 200 day moving average is $0.50. Plus Therapeutics has a one year low of $0.16 and a one year high of $2.31. The stock has a market capitalization of $98.40 million, a PE ratio of -0.37 and a beta of 0.82.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings data on Thursday, October 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). The company had revenue of $1.40 million for the quarter, compared to analyst estimates of $1.50 million. On average, sell-side analysts forecast that Plus Therapeutics will post -2.3 earnings per share for the current fiscal year.

Institutional Trading of Plus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Altium Capital Management LLC acquired a new stake in Plus Therapeutics in the third quarter valued at approximately $628,000. Scientech Research LLC bought a new stake in Plus Therapeutics during the 3rd quarter valued at $100,000. Jane Street Group LLC bought a new position in shares of Plus Therapeutics in the second quarter valued at $41,000. Susquehanna International Group LLP acquired a new position in shares of Plus Therapeutics during the third quarter valued at about $46,000. Finally, Virtu Financial LLC bought a new stake in shares of Plus Therapeutics during the first quarter worth about $38,000. 3.28% of the stock is owned by institutional investors.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.